Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on September 9, 2008
JNCI Journal of the National Cancer Institute 2008 100(18):1333-1334; doi:10.1093/jnci/djn271
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/18/1333    most recent
djn271v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hayes, D. F.
Right arrow Articles by Flockhart, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hayes, D. F.
Right arrow Articles by Flockhart, D.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

CORRESPONDENCE

Response: Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis

Daniel F. Hayes, Vered Stearns, James Rae, David Flockhart

Affiliations of authors: The Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI (DFH, JR); Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD (VS); Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN (DF)

Correspondence to: Daniel F. Hayes, MD, The Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 6312 Cancer Center, 1500 E. Medical Center Drive, Ann Arbor, MI (e-mail: hayesdf@umich.edu).

The first 10% of the full text of this article appears below.

We appreciate the support from Gurwitz and Newman regarding our cautiously written statements recommending further validation of the role of CYP2D6 to select appropriate antiestrogen therapy for patients with estrogen receptor (ER)–rich early breast cancer. However, we disagree with their statement that "the current evidence—taking into consideration the new Asian . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis
David Gurwitz and William Newman
J Natl Cancer Inst 2008 100: 1331. [Extract] [Full Text] [PDF]

Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis
Rowan T. Chlebowski and Nananda Col
J Natl Cancer Inst 2008 100: 1331-1332. [Extract] [Full Text] [PDF]